SCHEMBL10246963

SCHEMBL10246963

O=C1C=CCC=C1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18198948 0.73 ALDH1A1 (0.39)
SCHEMBL8056183 0.69
SCHEMBL15020100 0.69
SCHEMBL12629751 0.68
SCHEMBL14467763 0.65
SCHEMBL10602987 0.65
SCHEMBL12257159 0.64
SCHEMBL3292052 0.64 MAPT (0.37)
SCHEMBL15020363 0.64
SCHEMBL11548175 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2791251-A1 TRI-AROMATIC AZOMETHINE DIRECT DYES COMPRISING AT LEAST ONE UNIT DERIVED FROM RESORCINOL, DYEING COMPOSITION, METHOD AND USE L'OREAL (FR) 2014-10-22 EP claimed
WO-2013087772-A1 TRI-AROMATIC AZOMETHINE DIRECT DYES COMPRISING AT LEAST ONE UNIT DERIVED FROM RESORCINOL, DYEING COMPOSITION, METHOD AND USE L'OREAL (FR) 2013-06-20 WO claimed
US-9921479-B2 Resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2018-03-20 US disclosed
US-20160320699-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-11-03 US disclosed
US-20160320699-A1 RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2016-11-03 US disclosed
EP-3088955-A2 RESIST COMPOSITION AND PATTERNING PROCESS Shin-Etsu Chemical Co., Ltd. (JP) 2016-11-02 EP disclosed
US-9422388-B2 PU compositions containing complexed catalysts HENKEL AG & CO. KGAA (DE) 2016-08-23 US disclosed
US-20160038561-A1 TREATMENT OF ENDOMETRIOSIS, ANGIOGENESIS AND/OR ENDOMETRIAL LESION GROWTH SYNG PHARMACEUTICALS, INC. (CA) 2016-02-11 US disclosed
US-20140155445-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-06-05 US disclosed
US-8703698-B2 Compositions and methods for treating atherosclerosis THE UNIVERSITY OF CHICAGO (US) 2014-04-22 US disclosed
US-8629135-B2 Pharmaceutical compositions comprising RET inhibitors and methods for the treatment of cancer QUEEN'S UNIVERSITY AT KINGSTON (CA) 2014-01-14 US disclosed
US-20090291902-A1 INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE VERTEX PHARMACEUTICALS INCORPORATED 2009-11-26 US disclosed
US-20090221564-A1 Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease TRIGEN LIMITED (GB) 2009-09-03 US disclosed
US-20090176831-A1 Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System OSTA BIOTECHNOLOGIES (CA) 2009-07-09 US disclosed
US-20080311079-A1 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-12-18 US disclosed
US-20080221028-A1 Compositions and Methods for Treating Atherosclerosis THE UNIVERSITY OF CHICAGO 2008-09-11 US disclosed
US-7378422-B2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-05-27 US disclosed
US-7291590-B2 Compositions and methods for treating atherosclerosis QUEEN'S UNIVERSITY AT KINGSTON (CA) 2007-11-06 US disclosed
US-20070238667-A1 Compositions for treatment of cancer JIA, ZONGCHAO (CA) 2007-10-11 US disclosed
US-20070232545-A1 Compositions and Methods for Treating Atherosclerosis QUEEN'S UNIVERSITY AT KINGSTON (CA) 2007-10-04 US disclosed